A 78-year-old man with prostate cancer was referred for F-NaF PET/CT for assessing bone metastases. An F-NaF PET/CT study was performed after the intravenous administration of the radiopharmaceutical.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Five days later, a second study was done after oral administration of the radiopharmaceutical as part of a research protocol.
Clinical nuclear medicine. 2015 Nov 06 [Epub ahead of print]
Samara Riguete Zacchi, Rômulo Hermeto Bueno do Vale, Paulo Schiavom Duarte, Marcelo Tatit Sapienza, Carlos Alberto Buchpiguel
From the Division of Nuclear Medicine, São Paulo Cancer Institute (ICESP), São Paulo, Brazil.